Long-term virological follow up of patients with occult hepatitis C virus infection

Liver International

Volumn 31, Issue 10, 2011, Pages 1519-1524

  Castillo, Inmaculada ^a   Bartolomé, Javier ^a   Quiroga, Juan A ^a   Barril, Guillermina ^a,b   Carreño, Vicente ^a  

^a Fundacion para el Estudio de Las Hepatitis Virales   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

HCV RNA; Lymphoproliferative response; Occult HCV; PBMCs; Ultracentrifugation

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS C ANTIBODY; HEPATITIS C VIRUS RNA; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LONG TERM CARE; MALE; OCCULT HEPATITIS C VIRUS INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; RNA ISOLATION; T LYMPHOCYTE; ULTRACENTRIFUGATION; VIROLOGY; VIRUS DETECTION;

ADULT; AGED; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER; MALE; MIDDLE AGED; RNA, VIRAL; STATISTICS, NONPARAMETRIC; URSODEOXYCHOLIC ACID;

EID: 80053981265     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02613.x     Document Type: Article

References (28)

1. Bartendchlager R, Lohmann V. Replication of hepatitis C virus. J GenVirol 2000; 81: 1631-48.
2. Pham TNQ, MacParland SA, Mulrooney PM, et al. Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. J Virol 2004; 78: 5867-74.
3. Radkowski M, Gallegos-Orozco JF, Jablonska J, et al. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C. Hepatology 2005; 41: 106-14.
4. Radkowski M, Horban A, Gallegos-Orozco JF, et al. Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels. J Infect Dis 2005; 15: 1730-3.
5. Carreño V, Pardo M, López-Alcorocho JM, Rodríguez-Iñigo E, Bartolomé J, Castillo I. Detection of hepatitis C virus (HCV) RNA in the liver of healthy anti-HCV antibody-positive, serum HCV-RNA negative patients with normal alanine aminotransferase levels. J Infect Dis 2006; 194: 3-60.
6. Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bartolomé J, Carreño V. Hepatitis C virus replicates in the liver of sustained responder patients to antiviral treatment. Clin Infect Dis 2006; 43: 1277-83.
7. Castillo I, Pardo M, Bartolomé J, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004; 189: 7-14.
8. Esaki T, Suzuki N, Yokoyama K, et al. Hepatocellular carcinoma in a patient with liver cirrhosis associated with negative serum HCV test but positive liver tissue HCV-RNA. Intern Med 2004; 43: 279-82.
9. Comar M, Dal Molin G, D'Agaro P, Crocè SL, Tiribelli C, Campello C. HBV, HCV and TTV detection by in situ polymerase chain reaction could reveal occult infection in hepatocellular carcinoma: comparison with blood markers. J Clin Pathol 2006; 59: 526-9.
10. Zaghloul H, El-Sherbiny W. Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells. Immunol Invest. 2010; 39: 284-91.
11. Bokharaei-Salim F, Keyvani H, Monavari SH, et al. Occult hepatitis C virus infection in Iranian patients with cryptogenic liver disease. J Med Virol 2011; 83: 989-895.
12. De Marco L, Gillio-Tos A, Fiano V, et al. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. PLoS One 2009; 4: e8128.
13. Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-82.
14. Quiroga JA, Llorente S, Castillo I, et al. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. J Med Virol 2006; 78: 1190-7.
15. Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, Pardo M, Carreño V. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 2006; 80: 10972-9.
16. Pham TNQ, Coffin CS, Churchill ND, Urbanski SJ, Lee SS, Michalak TI. Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus. J Viral Hepat 2011; DOI: 10.1111/j.1365-2893.2011.01442.x [Epub ahead of print].
17. Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection. Aliment Pharmacol Ther. 2009; 30: 477-86.
18. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
19. Bartolomé J, López-Alcorocho JM, Castillo I, et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007; 81: 7710-5.
20. Bullock GC, Bruns DE, Haverstick DM. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem 2002; 48: 2147-54.
21. Kwok S, Higuchi R. Avoiding false positive with PCR. Nature 1989; 39: 237-8.
22. Rico MA, Ruiz S, Subirá D, et al. Virus-specific effector CD4 + T-cell responses in hemodialysis patients with hepatitis C virus infection. J Med Virol 2004; 72: 66-74.
23. Halfon P, Bourliere M, Ouzan D, et al. Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay. J Clin Microbiol 2008; 46: 2106-8.
24. Bernardin F, Tobler L, Walsh I, et al. Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 2008; 47: 1446-1152.
25. Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology 2010; 139: 1593-601.
26. Takano S, Ito Y, Yokosuka O, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558-64.
27. Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease. Eur J Gastroenterol Hepatol 1995; 7: 151-4.
28. Pardo M, López-Alcorocho JM, Castillo I, Rodríguez-Iñigo E, Perez-Mota A, Carreño V. Effect of anti-viral therapy for occult hepatitis C virus infection. Aliment Pharmacol Ther 2006; 23: 1153-9.